Inhibiting several phosphatases - among which are included specific serine/threonine and tyrosine phosphatases, and other non-specific acid and alkaline phosphatases – four phosphatase inhibitor ...

Nakamura et al. 18 reported that the serine/threonine protein phosphatase inhibitor calyculin A enhanced cell killing when cells were treated 30 min before X-ray irradiation.

Deciphera Pharmaceuticals LLC has patented new serine/threonine-protein kinase B-raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) inhibitors reported to be useful for ...

These phosphorylation events are detected using fluorescently-labeled anti-phospho-tryosine or anti-phospho-serine/threonine antibodies in real time with kinetic evaluation. Cell lysates are prepared ...

Pfizer Inc. has described serine/threonine-protein kinase (SIK) inhibitors reported to be useful for the treatment of arthritis, cancer, osteoporosis, atherosclerosis, inflammatory bowel disease, ...

Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a key regulator in inflammation and cell death and is involved in mediating a variety of inflammatory or degenerative ...

Okadaic acid is a potent inhibitor of serine–threonine phosphatase subclasses PP2A, PP1, and PP2B. (PP stands for protein phosphatase.) It is the inhibition of this enzyme that is a primary cause of ...

For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with ...

BI 860585 is a potent and selective ATP-competitive mTOR serine/threonine kinase inhibitor. It has been tested in a phase 1 trial with 90 patients with advanced solid tumors as single agent, in ...